Moreover, MIA-602 was found to inhibit the growth of gastric cancer in vitro and in vivo by blocking p21-activated kinase 1 (PAK1), STAT3 and NF-kB inflammatory pathways [25]. Here, NFKB1 is linked to gastric cancer.